Evidence map›Paper›PMID 27959887›Full record

ArticleBritish journal of cancer2017

Increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of bladder cancer.

Barbara Pardini, Clara Viberti, Alessio Naccarati, Alessandra Allione, Marco Oderda, Rossana Critelli, Mirko Preto, Andrea Zijno, Giuseppina Cucchiarale, Paolo Gontero and 3 more

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 45 citations in OpenAlex.

  1. Micronuclei: origins, assays, mechanisms, diseases and treatments.Signal transduction and targeted therapy · 2026
    Review
  2. Purebred dogs show higher levels of genomic damage compared to mixed breed dogs.Mammalian genome : official journal of the International Mammalian Genome Society · 2024
    Article
  3. Establishment ofHeliyon · 2023
    Article
  4. Genotoxicity of Marijuana in Mono-Users.Frontiers in psychiatry · 2021
    Article
  5. Review
  6. Micronucleus, nucleoplasmic bridge and nuclear bud frequencies in patients with laryngeal carcinoma.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2020
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Barbara PardiniHuman Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy.
Clara VibertiHuman Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy.
Alessio NaccaratiHuman Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy.
Alessandra AllioneHuman Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy.
Marco OderdaDepartment of Urology, Città della Salute e della Scienza, Corso Bramante 88, Turin 10126, Italy.
Rossana CritelliHuman Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy.
Mirko PretoDepartment of Urology, Città della Salute e della Scienza, Corso Bramante 88, Turin 10126, Italy.
Andrea ZijnoDepartment of Environment and Primary prevention, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome 00161, Italy.
Giuseppina CucchiaraleDepartment of Urology, Clinica Cellini, Via Cellini 5, Turin 10126, Italy.
Paolo GonteroDepartment of Urology, Città della Salute e della Scienza, Corso Bramante 88, Turin 10126, Italy.
Paolo VineisHuman Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy.
Carlotta SacerdoteUnit of Cancer Epidemiology, Center for Cancer Prevention (CPO-Piemonte), Via Santena 7, Turin 10126, Italy.
Giuseppe MatulloHuman Genetics Foundation-Torino (HuGeF), via Nizza 52, Turin 10126, Italy.
Italian institute for Genomic Medicine · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITImperial College London · GBIstituto Superiore di Sanità · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBladder cancer (BC) is among the most common malignancies worldwide. The identification of new biomarkers for early BC detection, recurrence/progression is urgently needed. The cytokinesis-block micronucleus assay (CBMN) evaluates chromosome damage in cultured human lymphocytes and micronuclei (MN) provide a convenient and reliable index of both chromosome breakage and loss.

methodsChromosomal damage (expressed as frequencies of MN, nucleoplasmic bridges and nuclear buds (NBUD)) was evaluated by CBMN assay in cryopreserved lymphocytes from 158 age/smoking-matched pairs of cases and controls in relation to BC risk, recurrence or progression. Moreover, non-muscle invasive BC (NMIBC) patients were characterised for 783 DNA repair gene polymorphisms for their possible association with the investigated cytogenetic end points.

resultsMN and NBUD frequencies were significantly higher in cases than in controls (P=0.001 and P=0.006, respectively), with the associations being stronger in NMIBC. In a logistic regression model, for each increase of one unit in the MN frequency, a 1.12 increased risk of developing NMIBC was observed. In NMIBC cases, 10 polymorphisms were associated with different MN frequencies after genotype stratification.

conclusionsA model including traditional BC risk factors, MN frequency and the selected polymorphisms differentially distributed in cases and controls improved BC patient identification. Understanding the meaning of systemic chromosomal damage in BC patients with respect to the general population may help to adopt specific prevention strategies and therapeutic intervention.

Indexed as

AdultAgedBiomarkers, TumorCase-Control StudiesDNA DamageHumansLymphocytesMaleMicronucleus TestsMiddle AgedPrognosisRisk FactorsUp-RegulationUrinary Bladder NeoplasmsBiomarkers, Tumor

Identifiers

PMID27959887
PMCPMC5243995
OpenAlexW2566346115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.